In May 2010, the the Food and Drug Administration's (FDA) Office of Prescription Drug Promotion(OPDP) (formerly the Division of Drug Marketing, Advertising, and Communications) announced the launch of the Bad Ad Program “to help health care professionals recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency.” The Bad Ad Program asks health care professionals to “recognize and report” to the FDA any activities or messages that may be false or misleading. OPDP will then review the complaints and take action when necessary. 

The OPDP recently launched an e-learning CME/CE course and case studies. The e-learning course is a one-hour, self-paced training to help HCPs and HCP students learn how to identify prescription drug promotion that may be misleading, raise other regulatory issues and report it to the FDA. The course will include seven modules: The Bad Ad Program, Principals of Persuasion, FDA Oversight of Prescription Drug Promotion and Marketing, Common Drug Promotion Issues, and Reporting Potential Drug Promotion Issues. Current and future HCPs, including physicians, physician assistants, nurses, nurse practitioners, and pharmacists are the target audience for the course.

OPDP has also developed several case studies based on recent enforcement letters for incorporation into the curriculum of HCP schools to raise awareness about misleading prescription drug promotion. According to OPDP, "these new resources will continue to raise awareness about misleading prescription drug promotion and the role that HCPs can play in reporting these issues to the FDA."